State Street SPDR S&P Pharmaceuticals ETF
XPH
84 hedge funds and large institutions have $205M invested in State Street SPDR S&P Pharmaceuticals ETF in 2018 Q3 according to their latest regulatory filings, with 25 funds opening new positions, 22 increasing their positions, 15 reducing their positions, and 9 closing their positions.
261% more call options, than puts
Call options by funds: $1.14M | Put options by funds: $316K
178% more first-time investments, than exits
New positions opened: 25 | Existing positions closed: 9
47% more repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 15
33% more capital invested
Capital invested by funds: $154M → $205M (+$50.2M)
20% more funds holding
Funds holding: 70 → 84 (+14)
5.47% more ownership
Funds ownership: 45.71% → 51.18% (+5.5%)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
HighTower Advisors
Chicago,
Illinois
|
+$15.5M |
| 2 |
Morgan Stanley
New York
|
+$14M |
| 3 |
Lazard Asset Management
New York
|
+$7.35M |
| 4 |
JP Morgan Chase
New York
|
+$5.42M |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$3.05M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$11.8M |
| 2 |
JGGDR
JGP Global Gestao de Recursos
Rio De Janeiro,
Brazil
|
-$6.45M |
| 3 |
Goldman Sachs
New York
|
-$2.28M |
| 4 |
Citadel Advisors
Miami,
Florida
|
-$1.82M |
| 5 |
VF
Virtu Financial
New York
|
-$1.5M |
XPH Hedge Fund Activity: Q3 2018 in Review
84 of the 4,391 institutional investors tracked by Wall St. Rank reported a position in State Street SPDR S&P Pharmaceuticals ETF (XPH) for Q3 2018, worth a combined $205M — up 33% from $154M a quarter earlier.
Buyers outnumbered sellers: 25 funds opened new XPH positions and 9 closed out — a net gain of 16 holders — while 22 added to existing stakes and 15 trimmed.
The largest buyer was HighTower Advisors, opening a new position worth an estimated $15.5M. The largest seller was Deutsche Bank, cutting an estimated $11.8M.
- 84 institutional investors held State Street SPDR S&P Pharmaceuticals ETF (XPH) as of Q3 2018, up from 70 in Q2 2018.
- Funds reported $205M of State Street SPDR S&P Pharmaceuticals ETF stock for Q3 2018, up 33% quarter-over-quarter.
- 25 funds opened new State Street SPDR S&P Pharmaceuticals ETF positions in Q3 2018 and 9 closed out, a net change of +16 holders.
- The largest State Street SPDR S&P Pharmaceuticals ETF buyer in Q3 2018 was HighTower Advisors, an estimated $15.5M added.
- The largest State Street SPDR S&P Pharmaceuticals ETF seller in Q3 2018 was Deutsche Bank, an estimated $11.8M sold.
Based on aggregated 13F filings for Q3 2018.